Nicotinic acetylcholine receptor alpha-6 subunit-containing subtype (alpha6* nAChR) (alpha6* nAChR)

Nicotinic acetylcholine receptor alpha-6 subunit-containing subtypes (alpha6* nAChRs) are a specialized group of ligand-gated ion channels primarily expressed in the midbrain dopaminergic system, including the substantia nigra and ventral tegmental area. These receptors play a critical role in modulating the release of dopamine and GABA, thereby influencing reward pathways and motor control. Due to their restricted expression on dopaminergic terminals, they are considered high-value therapeutic targets for Parkinson's disease, where their activation may compensate for lost dopaminergic tone, and for substance use disorders, where their inhibition can reduce the reinforcing effects of nicotine and alcohol. Genetic variations in the CHRNA6 gene, such as the rs2304297 polymorphism, have been linked to increased susceptibility to tobacco dependence and other addictive behaviors. Pharmacological targeting is challenging due to the high structural similarity between the alpha-6 and alpha-3 subunits, but selective tools like alpha-conotoxins MII and PIA have been instrumental in characterizing their function. Current research focuses on developing subtype-selective agonists and antagonists to treat neurodegenerative and psychiatric conditions without the side effects associated with broader nicotinic receptor activation.

Other names

CHRNA6alpha6-containing nicotinic acetylcholine receptoralpha6* nAChRCholinergic receptor nicotinic alpha 6 subunitnAChR alpha6

Drugs targeting alpha-6 subunit-containing nicotinic acetylcholine receptors typically act as agonists or partial agonists to stimulate presynaptic dopamine release in the striatum for the treatment of Parkinson's disease, or as antagonists to block the rewarding effects of nicotine and alcohol in addiction therapy.